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LETTER TO THE EDITOR
Moderate to severe ischemic mitral regurgitation: 
More data to guide the choice. Why not consider 
the use of subvalvular repair?
Antonio Nenna1, Massimo Chello1, Francesco Nappi2
1Department of Cardiovascular Surgery, Università Campus Bio-Medico di Roma, Rome, Italy 
2Department of Cardiac Surgery, Center Cardiologique du Nord, Saint-Denis, Paris, France
In a recent issue of Cardiology Journal, Li et al. [1] 
described long-term outcomes of mitral valve sur-
gery in patients with ischemic mitral regurgitation 
(MR). Using a propensity-score matched analysis 
with 77 pairs of patients and a median follow up of 
53 months, their results indicate that subvalvular-
sparing mitral valve replacement leads to reduced 
hospitalization for heart failure and improved 
ventricular remodeling, with no differences in mor-
tality. This study encourages scientific debate on 
this topic as an optimal treatment in patients with 
ischemic MR, which is far from being established.
Moving from anatomic details to mechanical 
aspects, the importance of restoring a functional 
mitral subvalvular apparatus has been increasingly 
considered a determinant for optimal treatment of 
ischemic MR. In fact, the Papillary Muscle Approxi-
mation Trial reported the safety and effectiveness 
of valvular and subvalvular repair (associated with 
complete myocardial revascularization), in patients 
with moderate to severe ischemic MR [2–4]. This 
“paradigm shift” in the concept of mitral valve repair 
is responsible for a flourishing of literature in recent 
years [1, 2, 5, 6], but awareness of the results of clini-
cal trials and reproducibility of surgical techniques 
are crucial for future studies.
The natural history of ischemic MR is hetero-
geneous and is largely determined by the severity 
of mitral failure, as a majority of patients with mild 
to moderate regurgitation remain asymptomatic 
and may have a near-normal life expectancy [7].
The untreated moderate ischemic mitral valve 
(with a restrictive mitral annuloplasty) by pre-
ferring coronary artery bypass grafting (CABG) 
alone did not lead to significant differences in left 
ventricular reverse remodeling at 2 years [8]. As 
demonstrated by the CTSN trial [8] in patients with 
combined restrictive mitral annuloplasty (RMA) 
and CABG, mitral-valve repair provided a more 
durable correction of MR but did not significantly 
improve survival (hazard ratio [HR] in combined-
procedure, 0.90; 95% confidence interval [CI] 
0.45–1.83; p = 0.78) or reduce overall adverse 
events (major adverse cardiac and cardiovascular 
events [MACCE], HR 0.89; 95% CI 0.60–1.34; 
p = 0.58) or improve readmissions for heart failure 
(CABG-alone vs. combined-procedure; p = 0.84). 
Conversely, the patients who underwent RMA 
combined to CABG were associated with an early 
hazard of increased neurologic events (combined-
procedure vs. CABG-alone p = 0.02) and su-
praventricular arrhythmias (combined-procedure 
vs. CABG-alone p = 0.04), at 2 years.
In patients with severe ischemic MR, expert 
consensus favors simultaneous correction of MR at 
the time of CABG operation [7]. Revascularization 
without mitral valve surgery does not significantly 
reduce moderate-to-severe MR, as described by in-
vestigators reporting recurrent moderate to severe 
ischemic MR in 77% of patients [9]. However, the 
central question remains under debate [4, 8, 10]: 
which strategy for mitral valve surgery is the most 
effective?
In support of mitral-valve repair achieved 
with a restrictive annuloplasty combined to papil-
lary muscle approximation (PMA), recent studies 
showed a relatively lower perioperative morbidity 
and mortality, associated with improvements in left 
www.cardiologyjournal.org 221
Antonio Nenna et al., Considerations from Papillary Muscle Approximation Trial
ventricular remodeling that is related to the pres-
ervation of the subvalvular apparatus [2–4]. On the 
other hand, the benefit of chordal-sparing mitral valve 
replacement (CS-MVR) is providing a more durable 
correction of MR with favorable ventricular remod-
eling [1, 10], albeit in association with no significant 
difference in cumulative mortality rates of major 
adverse cardiac or cerebrovascular events between 
patients who underwent CS-MVR or RMA [1, 10].
One study included 251 randomized patients 
to RMA or CS-MVR and reported no significant re-
duction in 2 year mortality with CS-MVR. The rate 
of death was 19.0% in the repair group and 23.2% 
in the replacement group (HR for RMA of 0.79, 
95% CI 0.46–1.35; p = 0.39) [10].The proportion 
of patients with recurrent moderate-to-severe MR 
at some point during the 2-year period was signifi-
cantly higher in recipients of RMA than in those 
who had CS-MVR (58.8% vs. 3.8%, p < 0.001). 
Li et al. [1] reported a significant reduction of 
hospitalization for heart failure in patients in the 
propensity score-matched RMA group than in the 
CS-MVR group (p = 0.015).The incidence of MR 
recurrence was significantly higher in the patients 
who received RMA (p < 0.001) while there were 
no significant differences in overall survival, free-
dom from cardiac death or MACCE for patients 
belonging to the two groups. Finally, multivariable 
analysis showed the use of RMA or CS-MVR was 
not a significant predictor of late overall death or 
MACCE (p = 0.997 and p = 0.260, respectively) [1].
Evidence from randomized controlled trial 
studies and meta-analysis strongly suggests that 
surgical intervention on the subvalvular apparatus 
is beneficial. RMA alone has been associated with 
a higher rate of recurrent MR compared with RMA 
associated with subvalvular procedures (such as 
PMA) [1–4, 10]. One study evaluated the effect of 
surgery on long-term outcomes in patients who 
had combined RMA and PMA (n = 48) or RMA 
(n = 48) alone for moderate-to-severe ischemic 
MR. No significant difference in terms of survival 
was found (HR for PMA 0.76; 95% CI 0.35–1.68; 
p = 0.502; log rank = 0.496) and in MACCE (HR 
for PMA 0.66; 95% CI 0.42–1.04; p = 0.073; log 
rank = 0.069). However, PMA patients had a sig-
nificantly better 5-years rate of recurrent MR than 
those managed with RMA alone (27% vs. 55.9%; 
p = 0.013). At 5 years, recurrence of severe MR, 
rehospitalization for heart failure and worsening 
of New York Heart Association class were lower 
among the PMA group [2–4]. The Papillary Muscle 
Approximation Trial has also demonstrated that the 
subvalvular procedure allows restoration of valve 
Figure 1. Indications and contraindications for papillary muscle approximation. This proposed algorithm remains to 
be further validated and supported by practice guidelines; CABG — coronary artery bypass grafting.
High levels of physical activity after CABG operation
Young/middle-aged adults without: mitral valve disease, large
myocardial scar tissue and with compromised viability, non
favorable mitral valve and subvalvular geometry; 
limited life expectancy < 15 years
Ideal anatomic substrate
Moderate to severe ischemic mitral regurgitation
Postero-basal myocardial infarction
Posteromedial papillary muscle: posterolateral displacement
Asymmetric tethering
Left ventricular end-diastolic diameter < 60 mm
Coaptation lenght < 12 mm
2
Tenting area < 26–30 mm
Interpapillary muscle distance < 40 mm
Suboptimal anatomic substrate
Mild to moderate ischemic mitral regurgitation
Postero-basal myocardial infarction with lateral extension
Posteromedial papillary muscle: lateral displacement
Symmetric tethering
Left ventricular end-diastolic diameter > 60 mm
Coaptation lenght > 12 mm
2
Tenting area > 26–30 mm
Interpapillary muscle distance > 40 mm
Subvalvular repair with
papillary muscle approximation
(any technique)
Subvalvular repair with
papillary muscle approximation
(any technique)
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geometry by correcting three crucial dimensions: 
interpapillary muscle distance, coaptation length, 
and anteroposterior annular diameter [2–4]. In an-
other randomized controlled trial, 101 patients with 
moderate-to-severe ischemic MR were evaluated 
(subvalvular repair n = 51; RMA n = 50) over 1 year; 
the rate of freedom from MR grade > 2 was 98% in 
subannular repair vs. 86.7% in RMA (p = 0.045), 
associated with an improvement in survival rate for 
subannular repair (100% vs. 90%, p = 0.025) [5].
Differences in results of clinical trials should 
be interpreted considering the heterogeneity in 
terms of surgical techniques of subvalvular repair. 
A standardization of procedures is warranted to 
produce comparable results. Successful valvular 
and subvalvular mitral-valve repair encompasses 
four general principles. First, combined repair 
must restore an adequate surface of coaptation 
of both leaflets in the systole with an adequate 
papillary muscle approximation [4]. Second, full 
leaflet motion must be restored with no restrictive 
movements of the leaflet related to subvalvular 
procedures. Third, to reduce the anteroposte-
rior diameter, a restrictive annuloplasty ring with 
a “two-size downsized” ring is used to adapt the ge-
ometry of mitral anulus to the dimension of the left 
ventricle. Last, but not least, the surgeon should 
ensure that no more than trivial MR is present at 
the completion of the repair to guarantee greater 
improvement of left ventricular remodeling and 
long-term durability of the repaired valve (Fig. 1).
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